Monoclonal antibody treatment is ineffective, limiting options for tackling COVID-19

The FDA has brought an end to the use of a key monoclonal antibody as a treatment for those who catch COVID-19, and have a weak immune system because it is no longer effective against the emerging omicron variants.

Read the full article here

Related Articles